市场调查报告书
商品编码
1347691
高内容放映市场:2023-2028 年全球行业趋势、份额、规模、增长、机会和预测High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球高内容放映市场规模达到12亿美元。展望未来,IMARC集团预计到2028年该市场将达到20亿美元,2023-2028年復合年增长率(CAGR)为8.4%。
高内涵筛选(HCS),也称为高内涵分析(HCA),是一种识别细胞表型和生物学偏差的自动显微镜方法。它有助于确定候选药物是否能改变病程,并识别改变细胞形态和表型的小分子,例如肽或 RNAi。它是药物发现中基于细胞的筛选的先进方法,结合了多色荧光成像的自动记录和高通量定量数据分析。它允许专业人员筛选和评估化合物对多个表观遗传标记的活性。因此,HCS 广泛应用于製药和生物技术公司、学术和政府机构以及合同研究组织 (CROS)。
阿尔茨海默氏症和帕金森氏症等慢性疾病和神经退行性疾病的患病率不断上升,是积极影响全球 HCS 需求的主要因素之一。此外,人口老龄化加剧,更容易患此类疾病,也促进了市场的增长。除此之外,领先企业正在推出与软件平台和人工智能(AI)系统集成的创新HCS设备,以提高筛查系统的可视化能力。这也可以归因于分析细胞分离和可扩展性的自动化系统的发展,这进一步提高了 HCS 技术的采用。此外,由于对负担得起的药物发现系统的需求不断增加,它们在製药行业中得到了广泛的应用。除此之外,许多国家的管理机构正在大力投资先进筛查系统的研发(R&D),以及医疗基础设施的显着改善,这创造了积极的市场前景。
The global high content screening market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.4% during 2023-2028.
High content screening (HCS), also known as high-content analysis (HCA), is an automated microscopy method of identifying cellular phenotype and biological deviations. It assists in determining whether a drug candidate modifies the disease course and identifying micro-molecules such as peptides or RNAi that alter the cell morphology and phenotype. It is an advanced approach to cell-based screening in drug discovery, which combines the automated recording of multicolor fluorescence imaging and high-throughput quantitative data analysis. It allows professionals to screen and evaluate the activity of compounds on multiple epigenetic marks. As a result, HCS is widely used in pharmaceutical and biotechnology companies, academic and government institutes, and contract research organizations (CROS).
The increasing prevalence of chronic disorders and neurodegenerative diseases, such as Alzheimer's and Parkinson's, represents one of the major factors positively influencing the demand for HCS around the world. In addition, the rising aging population, which is more prone to such ailments, is contributing to the market growth. Apart from this, leading players are introducing innovative HCS equipment that is integrated with software platforms and artificial intelligence (AI) systems to improve the visualization capabilities of the screening systems. It can also be attributed to the development of automated systems for analyzing cell separation and scalability, which has further improved the adoption of HCS technology. Furthermore, they find extensive application in the pharmaceutical industry due to the escalating need for an affordable drug discovery system. Besides this, governing agencies of numerous countries are considerably investing in the research and development (R&D) of advanced screening systems, along with significant improvement in the healthcare infrastructure, which is creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global high content screening market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and end-user.
Instruments
Cell Imaging and Analysis Systems
Flow Cytometers
Consumables
Reagents & Assay Kits
Microplates
Other Consumables
Software
Services
Accessories
Instruments dominate the market due to advances in instrumentation and automation techniques with advanced visualization capability and enhanced software platforms.
Target Identification and Validation
Primary Screening and Secondary Screening
Toxicity Studies
Compound Profiling
Other Applications
Primary screening and secondary screening currently dominates the market as primary screening helps in determining the microorganisms and organic acid in cells, whereas secondary screening assists in obtaining the quantitative and qualitative information about the cells, desired organisms or strains.
Pharmaceutical and Biotechnology Companies
Academic and Government Institutes
Contract Research Organizations (CROs)
High content screening (HCS) is widely utilized in pharmaceutical and biotechnology companies for various clinical and preclinical studies.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America holds the majority of the global high content screening share due to the increasing drug discovery research in the region.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific and Yokogawa Electric Corporation.